Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VATHOS study of budesonide + formoterol MDI versus budesonide MDI and open-label Symbicort Turbuhaler in inadequately controlled asthma
2021-002026-24Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Nov 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of budesonide + formoterol and budesonide in asthma (3 arms), sponsored by AstraZeneca. Primary endpoint: Change from baseline in morning pre-dose trough FEV1 over 24 weeks. Started Nov 2021; status: active.
02
Drugs
budesonide + formoterolbudesonide
03
Conditions
asthma
Beyond the preview
Go deeper on 2021-002026-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002026-24.